DexCom, Inc. (DXCM)
| Market Cap | 35.88B |
| Revenue (ttm) | 2.67B |
| Net Income (ttm) | 199.70M |
| Shares Out | 392.58M |
| EPS (ttm) | 0.42 |
| PE Ratio | 217.62 |
| Forward PE | 112.36 |
| Dividend | n/a |
| Ex-Dividend Date | Jun 13, 2022 |
| Volume | 2,872,675 |
| Open | 89.56 |
| Previous Close | 89.09 |
| Day's Range | 89.50 - 94.63 |
| 52-Week Range | 66.89 - 164.86 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 101.62 (+11.2%) |
| Earnings Date | Jul 28, 2022 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is ... [Read more...]
Financial Performance
In 2021, DexCom's revenue was $2.45 billion, an increase of 27.08% compared to the previous year's $1.93 billion. Earnings were $154.70 million, a decrease of -68.66%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for DXCM stock is "Buy." The 12-month stock price forecast is 101.62, which is an increase of 11.18% from the latest price.
News
2 Growth Stocks That Just Hit Setbacks: Are They Buys?
Did the market overreact to these companies' quarterly updates?
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Canaccord G...
Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM) System available on prescription in the UK, improving acc...
LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy t...
DexCom (DXCM) Q2 Earnings Match Estimates, Revenues Miss
Despite the top line missing estimates, DexCom's (DXCM) second-quarter results reflected strong domestic and international revenue growth.
Why DexCom Stock Is Falling Today
Investors didn't like the company's Q2 update.
DexCom (DXCM) Matches Q2 Earnings Estimates
DexCom (DXCM) delivered earnings and revenue surprises of 0% and 0.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
DexCom stock drops 17% after company's Q2 miss
DexCom Inc. DXCM, +1.39% shares fell nearly 17% in the extended session Thursday after the maker of glucose monitoring systems missed analyst expectations for its first quarter and tweaked higher its 20...
Dexcom Reports Second Quarter 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom Reports Second Quarter 2022 Financial Results
2 Reasons Why DexCom Stock Could Be a Smart Buy This Week
Its global ambitions are poised to drive further returns.
Dexcom G6 Continuous Glucose Monitoring System Mobile App Now Available in Spanish
SAN DIEGO--(BUSINESS WIRE)--Dexcom G6 Continuous Glucose Monitoring System Mobile App Now Available in Spanish
Is a Beat Likely for DexCom (DXCM) This Earnings Season?
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.
Here's Why You Should Hold On to DexCom (DXCM) Stock Now
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
Dexcom Canada Achieves Great Place to Work® Certification
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that it is certified as a Great Place to ...
1 Healthcare Stock Leading the Pack
Now might be the time to buy this healthcare stock.
Better Bear Market Buy: DexCom vs. Intuitive Surgical
Both of these disruptive healthcare companies could be big winners over the long term.
Is DexCom Stock Too Pricey to Buy?
Its valuation is expensive, but its future is quite bright.
Investors Wise to Steer Clear of Medtechs Providing Self-Pay Products, Services
Even after losing nearly 65% of its market value in the first half of the year, Align Technology Inc. ( ALGN , Financial) still does not look like anything approaching a buy. The Phoenix-area company ea...
This Stock-Split Stock Is a Better Buy Than GameStop
DexCom is more of a sure thing in the long run.
2 Dividend Stocks You Can Confidently Buy in a Bear Market
These dividend-paying superstars have been raising their payouts for generations.
Growth stocks remain resilient in weakening economy, says Neuberger's Jason Tauber
Jason Tauber, Neuberger Berman large cap disciplined growth and the disruptors portfolio manager, joins 'Closing Bell: Overtime' to discus his bullish case for the growth trade.
Dexcom Schedules Second Quarter 2022 Earnings Release and Conference Call for July 28, 2022 at 4:30 p.m. Eastern Time.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2022 financial results after market close on Thursday, July 28, 2022. Management will h...
3 Recent Stock Splits That Are Begging to Be Bought
Stock splits may serve as a bullish sign in a bearish market.
With Stock Splits Underway, These 2 Beaten-Down Stocks Are Buys Now
Don't be too quick to give up on these companies.
3 Stock-Split Stocks You Can Confidently Buy and Hold Forever
Among the high-profile stocks splitting their shares in 2022, these three offer the most attractive long-term growth prospects.